Combination Anabolic and Antiresorptive Therapy for Osteoporosis

Endocrinology and Metabolism Clinics of North America

Volumn 41, Issue 3, 2012, Pages 643-654

  Cusano, Natalie E ^a   Bilezikian, John P ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

Antiresorptive; Bisphosphonate; Combination therapy; PTH(1 34); PTH(1 84); Teriparatide

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; ZOLEDRONIC ACID;

BONE MASS; BONE REMODELING; BONE TURNOVER; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG ANTAGONISM; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERCALCEMIA; MONOTHERAPY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; VERTEBRA FRACTURE;

ANABOLIC AGENTS; ANIMALS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 84864827634     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2012.04.005     Document Type: Review

References (36)

1. Lindsay R., Cosman F., Zhou H., et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 2006, 21:366-373.
2. Bilezikian J.P. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep 2008, 6:24-30.
3. Graeff C., Timm W., Nickelsen T.N., et al. Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study. J Bone Miner Res 2007, 22:1426-1433.
4. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333:1437-1443.
5. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344-1352.
6. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
7. Saag K.G., Zanchetta J.R., Devogelaer J.P., et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009, 60:3346-3355.
8. Saag K.G., Shane E., Boonen S., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357:2028-2039.
9. Kurland E.S., Cosman F., McMahon D.J., et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000, 85:3069-3076.
10. Ettinger B., San Martin J., Crans G., et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745-751.
11. Miller P.D., Delmas P.D., Lindsay R., et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008, 93:3785-3793.
12. Boonen S., Marin F., Obermayer-Pietsch B., et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008, 93:852-860.
13. Boonen S., Milisen K., Gielen E., et al. Sequential therapy in the treatment of osteoporosis. Curr Med Res Opin 2011, 27:1149-1155.
14. Cusano N.E., Bilezikian J.P. Combination antiresorptive and osteoanabolic therapy for osteoporosis: we are not there yet. Curr Med Res Opin 2011, 27:1705-1707.
15. Cosman F., Wermers R.A., Recknor C., et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 2009, 94:3772-3780.
16. Lindsay R., Nieves J., Formica C., et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.
17. Lane N.E., Sanchez S., Modin G.W., et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998, 102:1627-1633.
18. Cosman F., Nieves J., Zion M., et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005, 353:566-575.
19. Cusano N.E., Bilezikian J.P. Teriparatide: variations on the theme of a 2-year therapeutic course. IBMS Bone Key 2010, 7:84-87.
20. Black D.M., Greenspan S.L., Ensrud K.E., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
21. Finkelstein J.S., Hayes A., Hunzelman J.L., et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216-1226.
22. Finkelstein J.S., Leder B.Z., Burnett S.M., et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 2006, 91:2882-2887.
23. Deal C., Omizo M., Schwartz E.N., et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005, 20:1905-1911.
24. Cosman F., Eriksen E.F., Recknor C., et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 2011, 26:503-511.
25. Gasser JA, Ingold P, Venturiere-Rebmann A, et al. Chronic subcutaneous, but not single intravenous, dosing of rats with bisphosphonates results in reduced bone anabolic response to PTH. In: American Society for Bone and Mineral Research 28th Annual Meeting. Philadelphia, September 15-19, 2006: F386; SA386.
26. Kurland E.S., Heller S.L., Diamond B., et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 2004, 15:992-997.
27. Black D.M., Bilezikian J.P., Ensrud K.E., et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005, 353:555-565.
28. Cosman F., Nieves J.W., Zion M., et al. Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int 2008, 19:529-535.
29. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
30. Lindsay R., Scheele W.H., Neer R., et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004, 164:2024-2030.
31. Prince R., Sipos A., Hossain A., et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005, 20:1507-1513.
32. Orwoll E.S., Scheele W.H., Paul S., et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9-17.
33. Kaufman J.M., Orwoll E., Goemaere S., et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005, 16:510-516.
34. Vahle J.L., Sato M., Long G.G., et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002, 30:312-321.
35. Harper K.D., Krege J.H., Marcus R., et al. Comments on Initial experience with teriparatide in the United States. Curr Med Res Opin 2006, 22:1927.
36. Harper K.D., Krege J.H., Marcus R., et al. Osteosarcoma and teriparatide?. J Bone Miner Res 2007, 22:334.